• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Abingworth appoints Robert DeBenedetto as Managing Director – Clinical Co-Development

    9/10/24 4:00:00 AM ET
    $CG
    Investment Managers
    Finance
    Get the next $CG alert in real time by email

    London, UK and New York, USA, September 10, 2024 - Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ:CG), today announced the appointment of Robert (Bob) DeBenedetto as Managing Director – Clinical Co-Development.

    Bob brings to Abingworth over 30 years of experience in the life sciences industry and will be working on Clinical Co-Development deals and execution with new and existing Abingworth portfolio companies. He will be based in Abingworth's Menlo Park, CA, USA office.

    Prior to joining Abingworth, Bob was the Founder, President and CEO of SFJ Pharmaceuticals Inc. (CA, USA), an Abingworth portfolio company, where he, together with Abingworth, pioneered the Clinical Co-Development strategy. This strategy combines bespoke investment and operational solutions to enable resource-constrained pharma companies to pursue additional clinical projects, and biotech companies to avoid near-term equity dilution.

    Under Bob's leadership, SFJ Pharmaceuticals was involved in the global development and approvals of multiple new therapeutics since its founding in 2009, including six in oncology, one rare blood disease therapy and one cardiovascular drug, some of which are marketed globally by Pfizer, Merck KGaA, Eisai and Apellis.

    Bob's early career positions included Vice President (VP) at Quintiles (now IQVIA), VP at Boston Scientific, and Senior Manager at EY. He currently serves on the boards of SFJ Pharmaceuticals and the Smithsonian Institution. In addition, Bob has previously served as a Senior Advisor to Blackstone Life Sciences.

    Kurt von Emster, Managing Partner & Head of Abingworth Life Sciences, said: "Bob was instrumental in establishing the Clinical Co-Development strategy with Abingworth some 15 years ago. We believe this strategy has proved successful time and again, bringing multiple innovative new therapies from our pharmaceutical and biotechnology partners to patients around the world. He is a fantastic addition to our team, significantly strengthening our ability to source and execute future deals as well as to advance existing programs, and we look forward to benefitting from his experience and expertise."

    Bob DeBenedetto added: "It has been extremely rewarding working with Abingworth over the past 15 years and being able to bring multiple new medicines to patients in need. I am thrilled to continue our long and productive collaboration, and to work even more closely with the excellent team in the US and UK to seek and advance new Clinical Co-Development opportunities."

    To date, Abingworth has raised over $1 billion in three Clinical Co-Development funds and has invested in 16 programs.

     

    Notes for Editors

    About Abingworth

    Abingworth is a leading transatlantic life sciences investment firm and part of the global investment firm Carlyle (NASDAQ:CG). Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 185 life science companies, leading to 50+ M&As and more than 75 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston.

    About Carlyle

    Carlyle (NASDAQ:CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $435 billion of assets under management as of June 30, 2024, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,200 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

    Contacts

    Kurt von Emster

    Managing Partner & Head of Abingworth Life Sciences

    Tel: +1 (650) 926 0600

    Bali Muralidhar

    Managing Partner, Chief Investment Officer & COO

    Tel: +44 (207) 534 1500

    www.abingworth.com

    For media enquiries:

    Mark Swallow or Frazer Hall, MEDiSTRAVA Consulting

    Tel: +44 (203) 928 9600

    Email: [email protected]



    Primary Logo

    Get the next $CG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CG

    DatePrice TargetRatingAnalyst
    7/10/2025$65.00Neutral → Buy
    Citigroup
    5/14/2025$56.00Hold → Buy
    TD Cowen
    3/19/2025Outperform → Perform
    Oppenheimer
    1/3/2025$60.00Peer Perform → Outperform
    Wolfe Research
    9/12/2024$42.00Equal Weight
    Wells Fargo
    8/27/2024$55.00Buy
    Redburn Atlantic
    8/6/2024$46.00 → $44.00Overweight → Neutral
    JP Morgan
    1/19/2024$40.00 → $41.00Buy → Neutral
    Citigroup
    More analyst ratings

    $CG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Carlyle Group upgraded by Citigroup with a new price target

    Citigroup upgraded Carlyle Group from Neutral to Buy and set a new price target of $65.00

    7/10/25 8:23:02 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Group upgraded by TD Cowen with a new price target

    TD Cowen upgraded Carlyle Group from Hold to Buy and set a new price target of $56.00

    5/14/25 8:48:54 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Group downgraded by Oppenheimer

    Oppenheimer downgraded Carlyle Group from Outperform to Perform

    3/19/25 8:14:15 AM ET
    $CG
    Investment Managers
    Finance

    $CG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acentra Health Named one of the 'Fastest Growing Companies' by the Washington Business Journal

    MCLEAN, Va., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to helping government and commercial healthcare clients and the populations they serve, has been named to the Washington Business Journal's Fastest Growing Companies list, which highlights private companies in the Washington, D.C., metropolitan area with the highest three-year sustained revenue growth rate. This marks the second consecutive year Acentra Health has been ranked among the region's fastest growing companies. In 2024, Acentra Health was listed as No. 26 out of 75 companies reviewed. Since that listing, the company has continued to experience sustaine

    9/17/25 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Prices $800 Million Senior Notes Offering

    WASHINGTON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) priced its offering of $800 million aggregate principal amount of 5.050% senior notes due 2035. The notes will be fully and unconditionally guaranteed by Carlyle's indirect subsidiaries Carlyle Holdings I L.P., Carlyle Holdings II L.L.C., Carlyle Holdings III L.P., and CG Subsidiary Holdings L.L.C. The offering is expected to close on September 19, 2025, subject to customary closing conditions. Carlyle intends to use the net proceeds from the sale of the notes for general corporate purposes. Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC

    9/16/25 4:56:00 PM ET
    $CG
    Investment Managers
    Finance

    Carlyle Announces Senior Notes Offering

    WASHINGTON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) today announced its intention to offer, subject to market and other conditions, senior notes. The notes will be fully and unconditionally guaranteed by Carlyle's indirect subsidiaries Carlyle Holdings I L.P., Carlyle Holdings II L.L.C., Carlyle Holdings III L.P., and CG Subsidiary Holdings L.L.C. Carlyle intends to use the net proceeds from the sale of the notes for general corporate purposes. Citigroup Global Markets Inc., Goldman Sachs & Co. LLC , J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. The off

    9/16/25 8:52:17 AM ET
    $CG
    Investment Managers
    Finance

    $CG
    SEC Filings

    View All

    The Carlyle Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Carlyle Group Inc. (0001527166) (Filer)

    9/19/25 4:16:41 PM ET
    $CG
    Investment Managers
    Finance

    SEC Form 8-K filed by The Carlyle Group Inc.

    8-K - Carlyle Group Inc. (0001527166) (Filer)

    9/16/25 8:12:26 PM ET
    $CG
    Investment Managers
    Finance

    SEC Form FWP filed by The Carlyle Group Inc.

    FWP - Carlyle Group Inc. (0001527166) (Subject)

    9/16/25 5:03:31 PM ET
    $CG
    Investment Managers
    Finance

    $CG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Conway William E Jr gifted 2,000,000 shares, decreasing direct ownership by 7% to 26,999,644 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    9/5/25 5:05:14 PM ET
    $CG
    Investment Managers
    Finance

    Chief Operating Officer Lobue Lindsay was granted 496 shares, increasing direct ownership by 0.10% to 476,225 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    8/29/25 4:55:04 PM ET
    $CG
    Investment Managers
    Finance

    General Counsel Ferguson Jeffrey W. was granted 744 shares, increasing direct ownership by 0.10% to 753,999 units (SEC Form 4)

    4 - Carlyle Group Inc. (0001527166) (Issuer)

    8/29/25 4:55:10 PM ET
    $CG
    Investment Managers
    Finance

    $CG
    Leadership Updates

    Live Leadership Updates

    View All

    New Medicaid Alliance to Tackle AI Safety and Standards Across States

    MCLEAN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better health outcomes for its clients and the populations they serve, today announced the launch of the Safe AI in Medicaid Alliance (SAMA), a collaborative initiative uniting Medicaid leaders, policy experts, and technology innovators to develop safe and responsible Medicaid-focused frameworks for artificial intelligence (AI) adoption and use. Created with input and participation from the Washington State Health Care Authority (HCA), the Arizona Health Care Cost Containment System (AHCCCS), Amazon Web Services (AWS), McKinsey & Co., Arcadia, an

    9/9/25 9:33:00 AM ET
    $CG
    Investment Managers
    Finance

    Acentra Health Names Marnie Keogh as Senior Vice President of Marketing

    MCLEAN, Va., July 21, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced today that Marnie Keogh has joined the company as Senior Vice President of Marketing. In this role, Keogh will lead the company's integrated marketing strategy, driving initiatives across brand development, digital marketing, thought leadership, and go-to-market campaigns. "Marnie brings a distinguished career in healthcare marketing and communications, with a proven ability to drive brand transformation, operational excellence, and digit

    7/21/25 9:47:00 AM ET
    $CG
    Investment Managers
    Finance

    SS&C Technologies to Acquire Calastone

    SS&C Technologies Holdings, Inc. (NASDAQ:SSNC) today announced a definitive agreement to acquire Calastone, the largest global funds network and leading provider of technology solutions to the wealth and asset management industries, from global investment firm Carlyle. The purchase price is approximately £766 million (approximately US $1.03 billion), subject to certain adjustments. Headquartered in London, Calastone operates the largest global funds network, connecting more than 4,500 of the world's leading financial organizations across 57 markets. The acquisition is expected to close in Q4 2025, subject to regulatory approvals. SS&C expects the acquisition to be accretive within 12 mont

    7/21/25 4:00:00 AM ET
    $CG
    $SSNC
    Investment Managers
    Finance
    Computer Software: Prepackaged Software
    Technology

    $CG
    Financials

    Live finance-specific insights

    View All

    Carlyle Prices $800 Million Senior Notes Offering

    WASHINGTON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) priced its offering of $800 million aggregate principal amount of 5.050% senior notes due 2035. The notes will be fully and unconditionally guaranteed by Carlyle's indirect subsidiaries Carlyle Holdings I L.P., Carlyle Holdings II L.L.C., Carlyle Holdings III L.P., and CG Subsidiary Holdings L.L.C. The offering is expected to close on September 19, 2025, subject to customary closing conditions. Carlyle intends to use the net proceeds from the sale of the notes for general corporate purposes. Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC

    9/16/25 4:56:00 PM ET
    $CG
    Investment Managers
    Finance

    Carlyle Announces Senior Notes Offering

    WASHINGTON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Global investment firm Carlyle (NASDAQ:CG) today announced its intention to offer, subject to market and other conditions, senior notes. The notes will be fully and unconditionally guaranteed by Carlyle's indirect subsidiaries Carlyle Holdings I L.P., Carlyle Holdings II L.L.C., Carlyle Holdings III L.P., and CG Subsidiary Holdings L.L.C. Carlyle intends to use the net proceeds from the sale of the notes for general corporate purposes. Citigroup Global Markets Inc., Goldman Sachs & Co. LLC , J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. The off

    9/16/25 8:52:17 AM ET
    $CG
    Investment Managers
    Finance

    Carlyle Secured Lending, Inc. Announces Financial Results For Second Quarter Ended June 30, 2025, Declares Third Quarter 2025 Dividend of $0.40 Per Common Share

    NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, "we," "us," "our," "CGBD" or the "Company") (NASDAQ:CGBD) today announced its financial results for its second quarter ended June 30, 2025. Justin Plouffe, CGBD's Chief Executive Officer, said, "Despite market uncertainty, the second quarter was another record quarter of originations for both CGBD and the broader Carlyle Direct Lending platform. With CGBD net financial leverage at the mid-point of our target range, we remain well positioned to benefit from the expected pickup in deal volume in the second half of the year. Although spreads in the overall market remain hist

    8/5/25 4:01:00 PM ET
    $CG
    $CGBD
    Investment Managers
    Finance
    Finance: Consumer Services

    $CG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Subject)

    11/15/24 5:22:29 PM ET
    $CG
    Investment Managers
    Finance

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

    10/21/24 4:31:27 PM ET
    $CG
    Investment Managers
    Finance

    Amendment: SEC Form SC 13D/A filed by The Carlyle Group Inc.

    SC 13D/A - Carlyle Group Inc. (0001527166) (Filed by)

    10/15/24 4:31:27 PM ET
    $CG
    Investment Managers
    Finance